Streetbeat News

Analyst Ratings

BMY

Investors with significant capital have shown a bearish stance on Bristol-Myers Squibb (BMY) through options trading. Benzinga's options scanner detected 15 unusual trades, with a slight majority being bearish. The stock is currently trading at $52.72, with analysts providing mixed ratings and price targets around $50-$53.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:16 pm

SLB

JP Morgan analyst Arun Jayaram maintains an Overweight rating on Schlumberger (NYSE:SLB) but lowers the price target from $64 to $60.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 6:15 pm

DBRG

JP Morgan analyst Richard Choe maintains an Overweight rating on DigitalBridge Group (NYSE:DBRG) and raises the price target from $22 to $23.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 6:05 pm

EQIX

JP Morgan analyst Philip Cusick maintains an Overweight rating on Equinix and raises the price target from $950 to $975.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 6:04 pm

DLR

JP Morgan analyst Richard Choe maintains an Overweight rating on Digital Realty Trust (NYSE:DLR) and raises the price target from $175 to $180.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 6:02 pm

IART

In the past three months, 10 analysts have rated Integra Lifesciences (NASDAQ:IART), with a mix of bullish and bearish perspectives. The average 12-month price target is $25.1, down from $27.11. Recent analyst actions include several downgrades and lowered price targets, reflecting changing market conditions and company performance.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:02 pm

SQ

Block (NYSE:SQ) has been analyzed by 11 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $84.91, down 6.79% from the previous $91.10. Analysts have adjusted their ratings and price targets, reflecting market conditions and company performance. Block's financials show positive revenue growth but challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:02 pm

TWST

Twist Bioscience (NASDAQ:TWST) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have set a 12-month average price target of $49.4, up 9.78% from the previous $45.00. The company's financials show a positive revenue trend but face challenges with net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:01 pm

SBRA

Analysts have varied ratings for Sabra Health Care REIT (NASDAQ:SBRA), with recent upgrades in price targets. The average 12-month target is now $18.75, up from $16.00, indicating positive sentiment. Sabra's financials show strong revenue growth and profitability, with a conservative debt approach.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:01 pm

GM

General Motors (NYSE:GM) has been analyzed by 12 analysts, showing a range of ratings from bullish to bearish. The average 12-month price target is $49.25, slightly down from $49.56. Analysts have adjusted their ratings and price targets, reflecting diverse opinions on GM's market position.

Portfolio Pulse from Benzinga Insights

October 01, 2024 | 6:01 pm